Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38.

This study aims to investigate the maximum tolerated dose, safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of GNTbm-38. Phase 1a is the dose escalation phase to firstly determine the MTD of patients with solid tumor. Once MTD for solid tumor patients has been established, the next lower dose of this MTD will serve as an initial dose to determine the MTD for patients with R/R PTCL. Phase 1b is the dose expansion phase in which optimal design is utilized to evaluate the safety, tolerability, and efficacy of GNTbm-38 in R/R PTCL patients.